Regeneron and Sanofi’s checkpoint inhibitor Libtayo (cemiplimab-rwlc) won U.S. Food and Drug Administration approval for the first-line treatment of patients with advanced non-small cell lung cancer whose tumors have high PD-L1 expression.

AstraZeneca Plc’s cancer drug Imfinzi was approved in Europe and Britain for a spaced-out regimen in a common type of lung cancer to help reduce the frequency of hospital visits while continuing treatment.

Amgen presented positive topline data from the Phase II CodebreaK 100 trial of sotorasib in KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC).

Sanofi and Regeneron halted a Phase III study of the checkpoint inhibitor Libtayo (cemiplimab) as a monotherapy treatment for advanced or metastatic non-small cell lung cancer due to early signs of significant improvement in overall survival.

China’s Innovent Biologics forged a licensing agreement with biosimilar-focused Coherus BioSciences to commercialize Innovent’s biosimilar candidate to Avastin (bevacizumab) in the United States and Canada.

About 40 percent of patients who received a combination of Bristol-Myers Squibb Co.’s immuno-oncology drugs Opdivo and Yervoy as an initial treatment for advanced non-small cell lung cancer were alive after two years, according to data presented at the European Society for Medical Oncology 2019 meeting.

Genentech announced positive data from the Phase III IMpower110 study evaluating Tecentriq as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT).

A combination of AstraZeneca’s lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations

Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).

Merck & Co.’s immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly diagnosed patients with advanced non-small cell lung cancer in a highly anticipated study.